Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cycloserine-containing short-course regimen trial for rifampicin-resistant tuberculosis
ChiCTR1800018833Phase 4Recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Jan 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of d-cycloserine in Rifampicin-resistant pulmonary tuberculosis (RR-PTB) (3 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Bacteriological outcome. Started Jan 2018; status: recruiting.
02
Drugs
d-cycloserine
03
Conditions
Rifampicin-resistant pulmonary tuberculosis (RR-PTB)
Beyond the preview
Go deeper on ChiCTR1800018833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018833.